Newborn Screening for SCID and Other Severe Primary Immunodeficiency in the Polish-German Transborder Area: Experience From the First 14 Months of Collaboration

Maria Giżewska, Katarzyna Durda, Theresa Winter, Iwona Ostrowska, Mariusz Ołtarzewski, Jeannette Klein, Oliver Blankenheit, Hanna Romanowska, Elżbieta Krzywińska-Zdeb, Michal Filip Patalan, Elżbieta Bartkowiak, Natalia Szczerba, Stefan Seiberling, Bozena Birkenfeld, Matthias Nauck, Horst von Bemuth, Christian Meisel, Elżbieta Bartkowiak, Michal Filip Patalan, and Małgorzata Pac

In 2017, in the Polish-German transborder area of West Pomerania, Mecklenburg-Western Pomerania, and Brandenburg, in collaboration with two centers in Warsaw, a partnership in the field of newborn screening (NBS) for severe primary immunodeficiency diseases (PIDs), mainly severe combined immunodeficiency (SCID), was initiated. SCID, but also some other severe PID, is a group of disorders characterized by the absence of T and/or B and NK cells. Affected infants are susceptible to life-threatening infections, but early detection gives a chance for effective treatment. The prevalence of SCID in the Polish and German populations is unknown but can be comparable to other countries (1:50,000–100,000). SCID NBS tests are based on real-time polymerase chain reaction (qPCR) and the measurement of a number of T cell receptor excision circles (TREC), kappa-deleting recombination excision circles (KREC), and beta-actin (ACTB) as a quality marker of DNA. This method can also be effective in NBS for other severe PID with T- and/or B-cell lymphopenia, including combined immunodeficiency (CID) or agammaglobulinemia. During the 14 months of collaboration, 44,287 newborns were screened according to the ImmunolVD protocol. Within 65 positive samples, seven were classified to immediate recall and 58 requested a second sample. Examination of the 58 second samples resulted in recalling one...
INTRODUCTION

Newborn screening (NBS) tests enable identification of infants with life-threatening disorders, which require early intervention shortly after birth.

NBS was initially implemented in the early 1960’s in the United States for the detection and treatment of phenylketonuria (1). Within the next years, this test was introduced in many other countries worldwide. Many rare genetic diseases, including inborn errors of metabolism and endocrine disorders, were successfully implemented to newborn screening programs later on. Different analytical techniques were used. These included bacterial inhibition tests, radioimmunoassays, immunoassays with colorimetric, fluorometric, or luminometric measurements and, starting from the late 1990’s, tandem mass spectrometry followed soon after by DNA-based technologies (2, 3). In 2005, McGhee et al. and Chan and Puck described the first-time application of the DNA–based assay (T-cell receptor excision circles—TREC) colorimetric NBS for severe combined immunodeficiency (SCID) and other forms of T-cell lymphopenia (4, 5). Some years later, KREC (kappa–deleting recombination circles) was proposed for a combined TREC—KREC screening approach for severe forms of T- and/or B-cells deficiencies, such as SCID, late-onset adenosine deaminase deficient SCID (ADA-SCID), combined immunodeficiency (CID), or different forms of agammaglobulinemia (XLA) (6, 7). Additionally, in ADA-SCID the purine metabolites and adenosine deaminase activity can be determined using tandem mass spectrometry (8, 9).

Primary immunodeficiency diseases (PID) are a heterogenous group of inborn errors of immunity affecting ~1 in 10,000 to 1 in 50,000 births (10). Currently, over 400 different genetic mutations and diseases are recognized, yet the collective prevalence is likely to be higher (11–13). Patients with PID are classified into one out of 10 groups, such as predominant antibody deficiency, cellular deficiency, combined immunodeficiency, and others (13). The leading symptom of the majority of them is a predisposition to life-threatening infections.

SCID is the most severe form of PID and represents a group of rare inborn defects of the immunity with either known (about 20) or unknown gene defects. The most common feature is the lack or very diminished number of T-cells, accompanied by absent or non-functional B lymphocytes and NK cells (13, 14). Affected individuals appear to be healthy at birth. They start to present infections and failure to thrive at the age of ~3–6 months. Severe and recurrent infections of bacterial, viral, fungal, and opportunistic origin, as well as secondary infections induced by life vaccines, are life-threatening with fatal outcomes within the first 1–2 years of life if untreated (15). Since the late 1960’s, many advances have been made in the field of treatment, including hematopoietic stem cell transplantation (HSCT), enzyme therapy, or gene therapy for different genetic forms of SCID (16, 17).

As a condition which is potentially curable if recognized and treated early, SCID and other severe PID meet Wilson’s and Jungner’s criteria for NBS (18, 19). TREC assay for NBS dedicated to the early diagnosis of SCID was implemented for the first time in the United States in 2008 (20). Several studies performed since that time revealed a SCID incidence of 1: 58,000 live births (21). Now it is screened throughout the United States (as one out of 35 primary screened disorders included in the recommended uniform screening panel), as well as in some countries in Europe and other continents, either reimbursed by governments or by scientific/pilot studies (2, 22).

Outside the United States, routine TREC screening is currently performed in Israel, New Zealand, Norway, Taiwan, several provinces in Canada, Switzerland, Iceland, Sweden, Italy (Tuscany), Spain (Catalonia), and in some regions in Australia (15). The overall implementation status EU-wide is very diverse. Considerations are still going on in various European countries. Pilot projects are currently underway or have been announced in France (23), Spain (24, 25), Norway, and the Netherlands (26).

In Germany, prior to the nationwide implementation of SCID NBS, only a few screening laboratories had experience with this procedure, such as laboratories in Munich (head: B. Olgemoeller), Heidelberg (head: G.F. Hoffmann), Hannover (head: N. Janzen), Leipzig (head: J. Thiery), and Greifswald (head: M. Nauck) (27). The whole process to include SCID in newborn screening began in 2012 with a local pilot trial in Leipzig. From 2014 to 2016, another pilot project was carried
out in Heidelberg. Finally, in August 2019 the SCID NBS was implemented nationwide (TREC only) (28). We present the results of the first 14 months of the trans-border cooperation in the field of NBS for SCID and other severe PID in the area of West Pomerania, Poland, and Mecklenburg-Western Pomerania and Brandenburg in Germany.

MATERIALS AND METHODS

The Polish-German transborder cooperation in the field of NBS for SCID and other severe PID was possible thanks to the Cooperation Program Interreg V A Mecklenburg-Vorpommern/Brandenburg/Poland and the project entitled “Innovative Polish-German cross-border program for early diagnosis and treatment of rare diseases in newborns—RareScreen” (INT10). The project was intended to expand the NBS panel for inborn errors of metabolism and other rare diseases including SCID. It was initiated on 01.05.2017 and will last till 30.10.2020.

The “RareScreen” project includes newborns born in the Euro-Pomerania region which covers West-Pomerania in Poland and Mecklenburg-Western Pomerania and part of Brandenburg in Germany. The population of the above-mentioned geographical regions in 2016 was as follows: 724,161 inhabitants in Mecklenburg-Vorpommern, 300,243 in Brandenburg (1,024,404 in total), and 1,708,174 in West Pomerania, Poland (29).

Three screening laboratories are involved in the project: Newborn Screening Laboratory Independent Public Clinical Hospital nr 1 PUM, Szczecin, Poland; Newborn Screening Laboratory, University Medicine Greifswald, Germany; and Newborn Screening Laboratory Charité University Medicine Berlin, Germany. The four other project partners are: University Medicine Greifswald, Germany; Pomeranian Medical University Szczecin, Poland; Institute of Mother and Child, Warsaw, Poland; and the Children’s Memorial Health Institute, Warsaw, Poland (Figure 1).

The results presented here are based on samples which were collected between October 24, 2018 and December 31, 2019. The sample collection is currently still ongoing and will last until October 2020.

For all newborns, the TREC and KREC NBS assay was performed in the NBS Laboratory in the Independent Public Clinical Hospital nr 1 PUM Szczecin (West Pomerania, Poland).

The organization of efficient transborder transport of dry blood spots samples (DBS) was fundamental to the cooperation between the NBS laboratories. The DBS from Berlin to Greifswald were sent via regular post. Subsequently, DBS from both German centers were delivered via courier from Greifswald to Szczecin NBS Laboratory. The transport between Greifswald and Szczecin took place four times a week and the samples were transported and stored at 4°C until use. The samples reached Szczecin usually within 1–7 days after their arrival in the local laboratories. The results were electronically transferred from Szczecin to Greifswald and Berlin within two working days. Waiting time for repetition from the first screening card of German newborns took from 2 to 10 days. Repetitions of the test from the first screening card of Polish newborns were performed in the next protocol which took place on the next working day. If any further action was needed, e.g., the necessity of taking a second screening card or admission of a newborn to the hospital for confirmatory tests, the procedure took place according to the protocols of each center.

Information brochures about the “RareScreen” program for parents and health care providers were distributed. Brochures included basic information about SCID, the goals and necessity of implementing this study, the advantages of participating in the project, and data protection. Additionally, informative meetings were organized for midwives, pediatricians, and other parties involved in the study. The aim of medical staff training and development of the brochures was to educate parents so that they could sign their informed consent to participate in the study.

No additional blood collection was needed from the newborns participating in the project apart from the blood usually taken for regular NBS. Heel prick blood samples were collected on filter paper (Whatman 903 for newborns from Poland and PerkinElmer 226 Ahlstrom for newborns from Germany) between the third and fifth day post-partum as part of the national NBS programs in Poland and Germany.

IT software (NeoBase) was adapted to transfer necessary data between centers involved in the project.

Demographic data, such as sex, birth date, data of sample collection, birth weight (BW), and gestational age (GA) of the newborns, was collected in the database (NeoBase). According to WHO definition, newborns were allocated to groups according to GA as follow: ≥38 weeks—born at term; ≥32–37 weeks—moderate preterm, ≥28–32 weeks—very preterm; <28 weeks—extremely preterm (30). Additionally, in the NeoBase other essential information about the newborns regarding their clinical condition, medicines taken (antibiotics, steroids), and blood
transfusions as well as the mothers’ history and treatment during pregnancy, was registered.

The NBS tests were performed using a commercial kit—SPOT-it™ TK (ImmunoIVD, Sweden). The screening laboratory in Szczecin was adapted and equipped with instruments for the PCR test method. Staff members were trained by the manufacturer of the TREC and KREC assay.

The 3.2 mm DBS were punched directly into 96-well-filter plate (ImmunoIVD) using a Wallac DBS puncher (Perkin Elmer). After DBS extraction and DNA elution, the qPCR reaction was performed (QuandStudio5, ThermoScience). The number of copies/µL for TREC, KREC, and beta-actin (ACTB) were calculated using the standard curves method. The amount of ACTB copy numbers indicates the efficacy of DNA extraction from DBS samples. Plates include three quality control punches with defined T- and B-cell ranges: T-cell depleted, B-cell depleted, and T-and B-cell depleted, as well as one blank control (DBS not soaked in blood) (QCs were provided also by ImmunoIVD).

Definition and Interpretation of the Results

The TREC and KREC assay is intended to screen newborns with the most severe forms of T- and B-cell lymphopenia (14, 31). According to the manufacturer’s instructions, the cut off values are 6 copies/µL for TREC and 4 copies/µL for KREC.

In the case of abnormal results (TREC <6 copies/µL and/or KREC <4 copies/µL) or inconclusive results (ACTB <1,000 copies/µL), a sample was repeated (re-tested) in duplicate from the first DBS. In the case of a positive NBS result, the following procedure depended on the values obtained from the first screening card (3 punches). When the value of TREC was in range of 1–4 and/or KREC 1–6 copies/µL, parents or medical staff (if the child was still at the hospital) were informed by letter or by phone call about the necessity of taking the second blood sample. Numbers of TREC and/or KREC <1 copies/µL in the re-tested first DBS (urgent-positive) resulted in immediate recall of the newborn and admission to the Department of Pediatrics, Endocrinology, Diabetology, Metabolic Diseases, and Cardiology in Szczecin and/or the Department of Immunology, The Children’s Memorial Health Institute, Warsaw, Poland or to the Department of Pediatric Pneumology and Immunology, Charité Universitätsmedizin Berlin, Germany for a confirmatory diagnosis. The aim of our program was to detect severe forms of PID, SCID in particular (defined as T-cells <300 cells/µL), as well as to identify other severe forms of T- and/or B-cell lymphopenia, including CID, agammaglobulinemia, and secondary immunodeficiencies (32). The confirmatory diagnostics procedures included, beside routine pediatric examination and basic laboratory tests, detailed immunocytopmetry assay (T cells [CD3/CD4/CD8, T cell naivy [CD45RA and CD45RO], B cells [CD19], NK cells [CD3/CD16/CD56], recent thymic emigrants (RTE) [CD4/CD31/CD45RA], α/β and γ/δ T cells [CD3/α/β TCR/γδ TCR], lymphocyte proliferation tests (to PHA, anti-CD3, and Pansorbin), humoral immunity adjustment (immunoglobulin levels), cytogenetic tests (karyotype), molecular tests (New Generation Sequencing or single gene sequencing by Sanger), and, if available and needed, radiosensitivity tests, analysis of the TCR Vbeta repertoire, ADA and PNP enzyme activity levels, and anthropometry.

False-positive results were defined when values for TRECs or KRECs in NBS were over the established cut-offs in absence of SCID or other PID in the confirmatory diagnosis (Figure 2).

Statistical analyses were performed using Python with the SciPy package. Given the beta distribution of the data, the Mann–Whitney test and the Kruskal–Wallis test were used to compare continuous variables between the groups. Differences were considered statistically significant when the p-value was <0.05.

RESULTS

A total of 44,287 newborn samples were prospectively collected from two centers in Germany (Greifswald—11,114; Berlin—15,428) and one in Poland (Szczecin—17,745). In this group of newborns, 22,804 (51.5%) were males and 21 434 (48.4%) were females. Information regarding the sex was incomplete in 49 (0.1%) cases and for 138 newborns (0.3%) GA was not provided. 36 634 (82.7%) newborns were born at term and 7,515 were preterm (17.0%). In a group of preterm newborns, there were 6,646 (15.0%) moderate preterm born at ≤32–37 weeks of gestation, 621 (1.4%) very preterm born between ≤28–31 weeks, and 248 (0.56%) extremely preterm children born <28 weeks. The median value for GA was 39 weeks (min. 22, max. 42 weeks). The median value for birth weight for the whole group was 3,395 g (min. 450 g, max. 5,504 g) (Table 1).

Out of 44,287 samples, 321 (0.72%) were re-tested from the first DBS. Among the 321 re-tested samples, 168 had a low number of ACTB (<1,000 copies/µL) and, due to a lack of sufficient amount of DNA in the sample, concomitant reduction of TRECs and KRECs were referred to as “inconclusive” and re-tested. The remaining 153 DBS with ACTB >1,000 copies/µL and TREC or KREC copy numbers below the respective cutoff values were considered “abnormal” and also re-tested. After re-testing, 256 newborns presented with normal results (TREC >6 copies/µL, KREC >4 copies/µL, ACTB >1,000 copies/µL); 65 neonates had positive results and required reevaluation. Out of this group, 11 (11/65; 16.92%) newborns had TREC value <6 copies/µL and 34 (34/66; 52.13%) retested children had KREC values <4 copies/µL. In two (2/65; 3.081%) newborns both TREC and KREC values were below the cut-off. In 18 (18/65; 27.70%) newborns, the poor-quality samples with undetected TREC and/or KREC copies and values of ACTB ≤1,000 copies/µL were detected, indicating insufficient efficacy of DNA extraction from DBS. In the case of eight newborns TREC and/or KREC copy values were below 1 copy/µL from the first blood samples (3 DBS punches). They were considered as urgent-positive and immediate admission to the hospital for clinical examination and flow cytometry was recommended, without waiting for the results from the second DBS. For the remaining 58 newborns, a second blood sample was requested. In the case of extremely and very preterm newborn (born <32 HBD) the second screening cards were taken when the child reached 32–34 weeks of gestational age. After re-testing the
second DBS, one newborn had a positive result and was called to further immunological evaluation; 56 newborns had normal results (Table 2).

In the whole group of tested children, extremely premature newborns, born <28 weeks of gestation, had the lowest TREC values (median value 42 copies/µL) and the lowest spread of the results among the groups (Figure 3A). TREC values in 5% of the first DBS from this group were below the cut-off value of 6 copies/µL, however, they also tended to rise along with GA. In our study, the Kruskal Wallis test showed significant differences (p < 0.05) in the values of TREC median between the studied groups of newborns divided according to the GA.

Regarding the KREC values, we did not notice higher rates of KREC results below cut off in children born <28 weeks of GA. However, in extremely premature newborns the spread of KREC values was greater than in the other groups. Children born between 32 and 37 and >38 weeks of gestation had similar distributions of KREC values (respectively median value: 41 and 42 copies/µL). The Kruskal-Wallis test shows a significant difference (p < 0.05) between the values of medians in the groups of newborns divided according to the GA (Figures 3A,B).
**TABLE 1** | Demographic data and median values of TREC and KREC copies/µL in the study population.

| Sample size | TREC copies/µL, median (SD; range) | KREC copies/µL, median (SD; range) |
|-------------|-----------------------------------|-----------------------------------|
| All newborns | 44,287 | 86 (54.8; 0–830) | 42 (33.0; 0–734) |
| **Sex** | | | |
| Male* | 22,804 (51.49%) | 81 (52.0; 0–830) | 40 (32.2; 0–734) |
| Female* | 21,434 (48.40%) | 92 (56.1; 0–758) | 44 (33.7; 0–600) |
| Unknown sex | 49 (0.11%) | 94 | 48 |
| **Term** | | | |
| ≥ 38 weeks; n (%) | 36,634 (82.71%) | 88 (54.8; 0–830) | 42 (31.8; 0–400) |
| Moderate preterm, ≥32–37 weeks; n (%) | 6,646 (15.01%) | 80 (51.8; 0–758) | 41 (34.2; 0–600) |
| Very preterm ≥28–31 weeks; n (%) | 621 (1.40%) | 68 (67.4; 0–498) | 45 (57.3; 0–734) |
| Extremely preterm <28 weeks; n (%) | 248 (0.56%) | 42 (44.3; 0–341) | 52 (61.4; 0–456) |
| Unknown term of birth | 138 (0.32%) | 94 | 45 |

*The Mann-Whitney test did not show a significant difference between males vs. females and TREC and KREC values.

**TABLE 2** | Number of newborns, retests from the first DBS, and recalls in the study population.

| Total | West pomerania szczecin | Mecklenburg-western pomerania greifswald | Brandenburg berlin |
|-------|-------------------------|----------------------------------------|-------------------|
| Newborns | 44,287 | 17,745 | 11,114 | 15,428 |
| Re-tested sample from the1st DBS | 321* | 116 | 105 | 100 |
| Re-call for confirmatory diagnosis after re-testing 1st DBS | 7 | 3 | 2 | 2 |
| Second sample | 58 | 23 | 15 | 20 |
| Re-call for confirmatory diagnosis after re-testing 2nd DBS | 1 | 1 | 0 | 0 |

*321 samples were re-tested from the first DBS (at least 2 punches): 168 “inconclusive”; results were related to low number of ACTB (<1,000 copies/µL) and subsequently reduced TREC and/or KREC values; - 153 “abnormal” results with ACTB >1,000 copies/µL had TREC and/or KREC copy numbers below the respective cutoff values.

**FIGURE 3** | The distribution of TREC copies/µL (A) and KREC copies/µL (B) in groups divided by GA. The fitted beta distributions of TREC (copies/µL) and KREC (copies/µL) values in four study groups: extremely preterm (blue line), very preterm (orange line), moderate preterm (green line), term newborn (red line).
Final Diagnosis
During the first 14 months of the “RareScreen” project, 44,287 newborns were screened for SCID. After testing the first screening cards, among 65 positive results with low TREC and/or KREC values, seven neonates treated as urgent-positive were recalled to the hospital for confirmatory tests. Examination of second screening samples from 58 newborns resulted in recalling to the hospital of one newborn. Overall, eight newborns were referred for further immunological evaluation. Confirmatory procedures (mostly lymphocyte subsets analysis) revealed one case of T-B<sub>low</sub>NK<sup>+</sup> SCID with severe cartilage-hair hypoplasia (homozygous mutation in RMRP G.70A>G), one case of atypical T<sub>low</sub>B<sub>low</sub>NK<sup>+</sup> CID without dysmorphic features and of unknown genetic defect, one case of autosomal recessive agammaglobulinemia, and one case of Nijmegen breakage syndrome. Among four other cases of T- and/or B-cell lymphopenia, one was related to the mother’s immunosuppression during pregnancy and one to prematurity. The next one, a child with slight dysmorphic features, presented low TREC only, followed by persistent/repeatable T-cell lymphopenia in flow-cytometry with normal TCR repertoire and mitogen stimulation. However, due to persistent T-cell lymphopenia, a molecular test (NGS) was performed, revealing no underlying genetic defects. At the age of 7 months, T-cell lymphopenia almost resolved, however the child remains under observation. The last newborn was truly false positive with normal results of flow-cytometry. In children with SCID and CID (pt.1 and pt.2), higher proportions of TCR γ/δ expression and loss of naivety were observed. In patient 1, diminished lymphoproliferation to phytohemagglutinin was observed. In patient 4 with Nijmegen breakage syndrome, only standard karyotype was performed, which resulted in changes in chromosome 7 and 14 (characteristic for this disease).

Both children with SCID and CID underwent a successful HSCT at the age of 2 and 3.5 months of age, respectively. In the child with agammaglobulinemia, immunoglobulin replacement therapy (IgRT) was introduced. The child with Nijmegen breakage syndrome required two instances of IgRT and remains under regular immunological monitoring. The other children with transient T- and/or B-cell lymphopenia are doing well and the immunophenotyping results are either normal or at least definitely improved.

The overall positive predictive value (PPV) was 50.0% (Table 3, Figure 4).

DISCUSSION
Six decades have passed since Robert Guthrie developed the population newborn screening test for PKU (1). During this time, the NBS evolved from detection of phenylalanine levels on filter paper to application of DNA-based technics for early identification of a number of rare genetic disorders.

Many authors agree that SCID, and other severe forms of PID, are an important health problem with a known natural history and available treatment, which meets the Wilson and Junger criteria (18, 19).
| TREC copies from 1st screening card cut-off ≤ 6 copies/µL | KREC copies from 1st screening card cut-off ≤ 4 copies/µL | ACTB copies from 1st screening card cut-off > 1,000 copies/µL | Final diagnosis | Treatment | Flow cytometry | Outcome |
|---|---|---|---|---|---|---|
| | | | | | | |
| 1 | 0–0 | 10.4–11.4 | 2,918–3,589 | T-B<sup>+</sup>NK+ SCID | HSCT at the age of 2 months | 70 (ref. 2,300–7,000) | 130 (ref. 600–1,900) | 8.54 (ref. 49.78–79.60%) | Alive |
| | | | | Cartilage-hair hypoplasia | | 5 (ref. 60–85%) | 9 (ref. 4–26%) | | |
| | | | | Homozygous mutation in RMRP g.70A>G | | | | | |
| 2 | 0.0–0.0 | 48–88 | 3,020–8,896 | T<sup>+</sup>lowB<sup>+</sup>NK+ CID | HSCT at the age of 3.5 months | 480 (ref. 2,300–7,000) | 240 (ref. 600–1,900) | 15.94 (ref. 49.78–79.60%) | Alive |
| | | | | Unknown genetic cause | | 38 (ref. 60–85%) | 18 (ref. 4–26%) | | |
| 3 | 144.5–163.4 | 0.9–0.6 | 6,186–10,409 | AR agammaglobulinemia | IgRT | 4,170 (ref. 2,300–7,000) | 93 (ref. 600–1,900) | 80 (ref. 49.78–79.60%) | Alive |
| | | | | homozygous IGLL1-mutation (IGLL1 c425C>T, p.Pro142Leu) | | 93 (ref. 60–85%) | 1 (ref. 4–26%) | | |
| | | | | The parents are each heterozygous for this mutation | | | | | |
| 4 | 2.1–3.1 | 0.6–0.7 | 4,104–4,356 | Nijmegen breakage syndrome, homozygous deletion c.657_661del5 in NBN gene | IgRT | 1,171 (ref. 1,700–3,600) | 45 (ref. 500–1,500) | 45.57 (ref. 50–74%) | Alive |
| | | | | | | 56.06 (ref. 58–67%) | 2.17 (ref. 19–31%) | | |
| | | | | | | 1.581* (ref. 2,000–4,700) | 113* (ref. 700–2,400) | 22.7* (ref. 50–74%) | |
| | | | | | | 49.9* (ref. 54.8–80.5%) | 3.57* (ref. 10.0–30.7%) | | |
| 5 | 12.1–22.1 | 0–0.2 | 4,909–3,208 | Transient B-cell lymphopenia due to mother’s immunosuppression during pregnancy (Mycophenolate Mofetil—in the first gestation weeks, prednisone, azathioprine, and tacrolimus)—flow cytometry results normalized with age | No | 2,420 (ref. 1,700–3,600) | 10 (ref. 500–1,500) | 31.1 (ref. 50–74%) | Alive |
| | | | | | | 95.61 (ref. 58–67%) | 0.38 (ref. 19–31%) | | |
| | | | | | | 5,901* (ref. 2,000–4,700) | 2,870* (ref. 700–2,400) | 56.6* (ref. 52–57%) | |
| | | | | | | 62.31* (ref. 57.1–72.4%) | 30.3* (ref. 18.4–37.5%) | | |

(Continued)
## TABLE 3 | Continued

| TREC copies from 1st screening card cut-off ≤ 6 copies/µL | KREC copies from 1st screening card cut-off ≤ 4 copies/µL | ACTB copies from 1st screening card cut-off > 1,000 copies/µL | Final diagnosis | Treatment | Flow cytometry | Outcome |
|---|---|---|---|---|---|---|---|
| | | | | | T cell | B cell | RTE cell |
| | N° cells/µL | % | N° cells/µL | % | N° cells/µL | % |
| 6. | 0.5–0.1 | 12.18–7.0 | 755–1,117 | T- and B-cell lymphopenia due to prematurity (GA−33 weeks). On molecular testing (WES)—no data for PID, in the HBD gene heterozygous pathogenic variant c.82G>T p. [Ala28Ser] was identified—the result is consistent with the genetic diagnosis of AD delta-thalassemia. Follow-up flow cytometry results improved with age | No | 522 (ref. 1,700–3,600) 47.64 (ref. 56–67%) | 222 (ref. 500–1,500 20.27 (ref. 19–31%) | 45.57 (ref. 49.78–79.60%) | Alive |
| | 1,133* (ref. 2,000–4,700) 30.4* (ref. 57.1–72.4%) | 1,625* (ref. 700–2,400) 43.9* (ref. 18.4–37.5%) | 27.1 (ref. 52–57%) |
| 7 | 0.0–1.0 | 101.3–80.1 | 1,334–2,528 | T-cell lymphopenia of unknown reason—follow-up flow cytometry results improved with age Unknown genetic cause | No | 1,250 (ref. 1,700–3,600) 56.14 (ref. 58–67%) | 635 (ref. 500–1,500) 2.53 (ref. 19–31%) | – | Alive |
| | 637* (ref. 2,000–4,700) 37.7* (ref. 57.1–72.4%) | 904* (ref. 700–2,400) 53.47* (ref. 18.4–37.5%) | 56.1* (ref. 52–77%) |
| | 2,745** (ref. 2,800–5,700) 50.6** (ref. 58.5–77.1%) | 2,240** (ref. 700–2,800) 41.3** (ref. 15.7–34.1%) | 82.6** (ref. 55–77%) |
| 8 | 0.0–0.0 | 74.3–54.8 | 1,639–705 | False positive | No | 2,880 (ref. 3,000–7,000) 61 (ref. 60–85%) | 940 (ref. 600–1,900) 20 (ref. 4–26%) | 68.87 (ref. 60.9–80.6%) | Alive |

Range of results from the first screening card includes 3 measurements (first test and repetition in duplicate). Differences in age-related values of flow-cytometry parameters arise from differences in laboratory specific referential ranges of flow-cytometry.

SCID, severe combined immunodeficiency; CID, combined immunodeficiency; TREC, T-cell receptor excision circles; KREC, kappa-deleting element recombination circle; ACTB, beta-actin; HSCT, hematopoietic stem cell transplantation; AR, autosomal recessive trait of inheritance; IgRT, immunoglobulin replacement therapy; GA, gestational age; PID, primary immunodeficiency diseases; RTE, recent thymic emigrants; AD, autosomal dominant trait of inheritance; WES, whole exome sequencing; GA, gestational age.

*repeated flow cytometry in 2nd-3rd month of life.

**repeated flow cytometry in 7nd-8th month of life.
Since 2008, TREC analysis has been used as a screening method for severe forms of primary T-cell lymphopenia (2, 5, 20, 33). Further research enabled the extension of the qPCR method to simultaneous measurement of TREC and KREC values. The method, which includes KREC analysis to assess potential B-cell lymphopenia, allows for additional identification of patients with XLA, Nijmegen breakage syndrome, and purine nucleoside phosphorylase (PNP) deficiency (9, 34). However, TREC screening will not identify infants with SCID in which a molecular defect lies downstream of T-cell receptor rearrangement, including variants in ZAP70, MHC class II (major histocompatibility complex class II), and ADA (delayed-onset disease) (35–39).

Infants with SCID and other forms of PID are susceptible to life-threatening infections of different origins, as well as secondary infections induced by life vaccines (40). Early diagnosis was made possible by testing T- and/or B-cell lymphopenia with NBS procedures, thereby significantly improving the life of affected children. Detection of PID in the first weeks of life enables an effective treatment with HSCT, enzyme replacement therapy, gene therapy, and/or immunoglobulin replacement therapy (16, 17, 19).

Nowadays, more and more countries have already introduced or are considering the population NBS for PID using the evaluation of TREC alone or in combination with KREC analysis (19, 41).

In our study we used the combined TREC and KREC assay. It is similar to the methods used in other centers, including those in Sweden, Iran, and Spain (33, 34, 42, 43). The study by Borte et al. gave the first specific TREC/KREC cut-off values for SCID NBS after retesting DBS samples of known SCID patients. Their findings were supported by further studies which then allowed conclusions about specificity and sensitivity (34). Barbaro et al., performed a population wide NBS using a combined TREC/KREC test with a cohort study size of 58,834 Swedish newborns from Stockholm county (33). Their findings were supported by studies performed in Sweden, Spain, and Germany with a specificity of >99% and sensitivity of >95% for the detection of severe T- and/or B-cell lymphopenia in dry blood material (24, 34). The study from the Stockholm/Upssala and Leipzig regions showed a PPV of 46% for severe T- and/or B-cell deficiency using the threshold values <6 copies/µL for TREC and <4 copies/µL for KREC. After evaluating the control-screening card, a PPV of 100% was found (34). In comparison, the following PPVs for severe T-cell deficiency was published based on data from the USA for TREC screening alone: State of Wisconsin 47%, State of California 31%, State of New York 18%, and State of Massachusetts 37%. Currently, the negative predictive value is 99% (44).

During the first 14 months of the RareScreen project, 44,287 newborns from Poland and Germany were screened. Overall, nine positive cases (including seven urgent-positive) were referred for immunological assessment starting with flow cytometry and followed by further investigations. Approximately, 1,5536 of tested newborns underwent further confirmatory procedures in our cohort, while in the United States the number ranged from 1:735 to 1:7,500 depending on the state, and in Sweden it was 1:20,000 (21, 33).

Out of eight newborns, one case of SCID and one case of CID were diagnosed. The recognition of two patients with SCID/CID in the studied population of 44,287 newborns demonstrates the efficacy of NBS with TREC evaluation in early detection of affected individuals, but at the same time it requires careful consideration as the number of screened newborns is still very limited. The next child, presenting with normal TREC but low KREC levels, was diagnosed with autosomal recessive agammaglobulinemia. In another newborn, with low KREC and diminished TREC as well as microcephaly and dysmorphic features, Nijmegen breakage syndrome was recognized with a variant in the NBN gene typical for the Slavic population. These two cases prove that the combined TREC/KREC testing should be considered as a powerful tool for initial screening of not only SCID suspected patients but also individuals with other severe PID. The introduction of combined TREC and KREC tests can significantly advance early diagnosis of inborn errors of immunity, such as agammaglobulinemia, Nijmegen breakage syndrome, ataxia-teleangiectasia or DiGeorge syndrome, as well as late-onset ADA SCID (33, 45–48). It allows for the early introduction of the proper treatment and prophylaxis (ex. HSCT, IgRT) before infectious complications appear or to avoid X-ray exposition in the case of Nijmegen breakage syndrome, ataxia-teleangiectasia, or other radiosensitive syndromes.

One positive result with a low KREC value was related to the mother's immunosuppression during pregnancy. The mother was treated with Mycophenolate Mofetil (in the first weeks of gestation), prednisone, azathioprine, and tacrolimus after a liver transplant due to autoimmune hepatitis. It is known that azathioprine may cross the placenta and B lymphocytes are more sensitive to drug-induced apoptosis than T lymphocytes (49). Two similar cases were described by Filipe et al. in Spain (24). Although the patient's initial flow cytometry on the eleventh day of life revealed significant lymphopenia, including reduced numbers of CD19+ B cells and milder diminished number of CD4+/CD3+ T cells and NK cells, repeated evaluation at the first and second month of age showed a normalisation of lymphocytes. This case shows that communication between neonatal/paediatric departments and screening laboratories is crucial in successful patient management. The knowledge about what medical treatment mother and/or the newborn underwent, may help to determine adequate follow-up steps.

In one premature neonate, born at the thirty-third week of gestation, initial low TREC resulted in recall for further evaluation. Although the first lymphocyte immunophenotyping revealed reduced numbers of CD19+B cells, CD3+, and CD4+ B cells, CD4+ naïve T cells as well as reduced T cell subpopulations, normalisation of CD19+B and significant improvement of CD3 subpopulation were noted in the repeated tests at the second and seventh month of life. It is worth underlining that TREC levels obtained in our study decreased with lower GA. It was especially apparent in children born <28 weeks of gestation. Such observations have been reported in several other publications (32, 50). Regarding the KREC values, we did not notice a higher rate of KREC results below cut off in children born <28 weeks.
of GA. However, a significant difference between KREC values in the groups of newborns divided according to the GA was shown. In groups of extremely premature and very preterm newborns, the spread of KREC values was greater than in children born ≤32 weeks. In a study by Kanegae et al., KREC values did not vary according to GA and in the studies by Barbaro et al. and de Felipe et al. KREC levels did show a downward trend with decreasing GA (25, 50). Further evaluation is needed and may provide data to define the reason for these differences and their clinical implications.

In the whole study group, there was one truly false positive case (low TREC with normal T-cell in flow-cytometry) of unknown reason. Pilot screening performed by Holodnij et al. proved that blood collection is crucial for proper determination of TREC and KREC values. Newborn heel blood should be applied directly to the screening card. Blood applied from capillaries or heparinized blood collection tubes should be avoided as heparin is known to inhibit DNA polymerases resulting in low values of TREC and KREC and/or ACTB copies number (51). Furthermore, insufficiently soaked screening cards also tend to lead to low TREC/KREC results. The company providing SCID kits recommend using the center part of DBS, which could not be ensured for all used samples, especially in the beginning of our study.

In our study many assays, depending on necessity and availability, were used to confirm the diagnosis of severe PID following positive screening tests. The confirmation algorithms vary in different countries or even by state. In some centers they are routinely limited to complete blood count (CBC) and lymphocyte profile only with extension to TCR repertoire, mitogen stimulation, or, if needed, to maternally engrafted cells assessment (32, 52, 53). Rechavi et al. suggested an initial confirmatory panel with complete blood count, full lymphocyte profile, and TREC quantification in the peripheral blood (32). In our region CBC, lymphocyte subset with TCR, and mitogen tests are done routinely, followed by supplementary assays according to clinical and laboratory deviation.

In summary, we can conclude that newborn screening programs, including TREC and KREC, followed by detailed immunological assessment, are of great value to avoid complications in children with undiagnosed PID.

**STRENGTHS AND LIMITATIONS OF THE STUDY**

The strength of our study is the introduction of a combined TREC and KREC analysis, which allows the detection of not only SCID but also other severe PID with accompanying T- or B-cell lymphopenia. The recall frequency of 1: 5,536 is acceptable, however, we can expect that with growing experience (at the departments of neonatology and in NBS laboratories) and populations screened the frequency of recalls will be further reduced. Positive predictive values for SCID and other severe PID was 50.0% which was comparable to other studies (45).

As from August 2019, the national NBS program based on TREC has only been implemented in Germany and the comparison of pro and cons between both programs (with or without KREC) will be possible. Based on the literature data and our still very limited experiences, we believe that by determining KREC, patients with congenital severe B-cell lymphopenia can also be identified. With the help of KREC copies evaluation, compared to an isolated TREC screening, SCID patients who suffer from a prevalent B-cell deficiency at birth, such as the “delayed-onset” ADA or purine nucleoside phosphorylase (PNP) deficiency, can also be detected (9, 34, 39). In addition, using KREC screening newborns with agammaglobulinemia (e.g., Bruton disease) can be identified at birth and consequently treated before serious infections occur. This leads to the prevention of lethal and serious infections with irreversible organ damage (mostly bronchiectasis), which has a lasting impact on the development of the affected children (54). A combined TREC and KREC screening is also advisable in terms of the fact that it would not involve any technically complex changeover, however the established screening algorithm would need to be changed.

However, the small population of selected regions is a limitation of the study, not allowing conclusions on the exact prevalence and incidence of SCID and other severe PID in other countries. At the same time, the study shows that cross-border cooperation between several screening centers can very efficiently combine their complementary expertise on such rare diseases. This can compensate for the fact that corresponding capacities cannot be maintained at all locations.

This is the first population screening study that allowed identification of newborns with T and/or B immunodeficiency in Central and Eastern Europe. It shows that newborn screening for severe PID, including different types of SCID, is effective and should be implemented into population obligatory panels for NBS and, to this effect, international cooperation proved to be efficient.

**DATA AVAILABILITY STATEMENT**

The datasets generated for this study are available on request from the corresponding author.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by Ethic Committee at the Pomerior Medical University in Szczecin, Poland (EA2/119/18), Ethic Committee of the University Medicine Greifswald, Germany (BB 081/18), Ethic Committee of the University Medicine Charité, Berlin, Germany (EA2/119/18). Written informed consent to participate in this study was provided by the participants' legal guardian/next of kin.

**AUTHOR CONTRIBUTIONS**

MG and MP designed the concept of the manuscript. TW, MG, MN, MO, MP, SS, OB, and TW designed the concept of the RareScreen project. MG, TW, and SS were coordinators for the project funding. TW, KD, OB, JK, EB, and NS did the laboratory work. KD and MO did the statistical analysis. MG, MP, KD,
The project and publication was founded by the Cooperation Programme Interreg V A Mecklenburg-Vorpommern/Brandenburg/Poland and project entitled Innovative Polish-German cross-border program for early diagnosis and treatment of rare diseases in newborns – RareScreen (INT10).

ACKNOWLEDGMENTS

We wish to express our gratitude to Stephan Borte MD, PhD (ImmunDefektCentrum Leipzig), Jeffrey Modell Diagnostic and Research Center for Primary Immunodeficiencies, Leipzig, Germany for providing excellent guidance during the implementation of the screening methods in the Newborn Screening Laboratory in Szczecin, Poland, as well as for valuable training of the laboratory staff and for his invaluable advice throughout the RareScreen project.

REFERENCES

1. Guthrie R, Susi A. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatr Res. (1963) 32:338–43.
2. Rajabi F. Updates in newborn screening. Pediatr Ann. (2018) 47:187–90. doi: 10.3928/19382359-20180426-01
3. Millington DS, Kodo N, Roe CR, Chace DH. Tandem mass spectrometry: a new method for acylcarnitine profiling with potential for neonatal screening for inborn errors of metabolism. J Inher Metab Dis. (1990) 13:321–4. doi: 10.1007/BF01793835
4. McGhee SA, Stehlm ER, Cowan M, Krosgstad P, McCabe ERB. Two-tiered universal newborn screening strategy for severe combined immunodeficiency. Mol Genet Metab. (2005) 86:427–30. doi: 10.1016/j.ymgme.2005.09.005
5. Chan K, Puck JM. Development of population-based newborn screening for severe combined immunodeficiency. J Allergy Clin Immunol. (2005) 115:391–8. doi: 10.1016/j.jaci.2004.10.012
6. van Zelm MC, Szczepanski T, van der Burg M, van Dongen JJM. Replication history of B lymphocytes reveals homeostatic proliferation and extensive antigen-induced B cell expansion. J Exp Med. (2007) 204:645–55. doi: 10.1084/jem.20060964
7. Nakagawa N, Inai K, Kanegane H, Sato H, Yamada M, Kondoh K, et al. Quantification of k-deleting recombination excision circles in Guthrie cards for the identification of early B-cell maturation defects. J Allergy Clin Immunol. (2011) 128:223–5.e2. doi: 10.1016/j.jaci.2011.01.052
8. Al-Dirbashi OY, Ogrel S, McIntosh N, Higgins L, McRoberts C, Fisher L, et al. Tandem mass spectrometric determination of purine metabolites adenosine deaminase activity for newborn screening of ADA–SCID. LymphoSign J. (2015) 2135–45. doi: 10.14785/lpsn-2014-0024
9. La Marca G, Canessa C, Giocaliere E, Romano F, Malvagia S, Funghini S, et al. Diagnosis of immunodeficiency caused by a purine nucleoside phosphorylase defect by using tandem mass spectrometry on dried blood spots. J Allergy Clin Immunol. (2014) 134:155–9. doi: 10.1016/j.jaci.2014.01.040
10. Buckley RH. Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution. Annu Rev Immunol. (2004) 22:625–35. doi: 10.1146/annurev.immunol.22.021703.104614
11. Bousfiha A, Jeddale L, Picard C, Al-Herz W, Ailié F, Chatila, et al. Human inborn errors of immunity: 2019 update of the IUIS phenotypical classification. J Clin Immunol. (2020) 40:66–81. doi: 10.1007/s10875-020-00758-x
12. Mandola AB, Reid B, Sorrir R, Brager R, Dent P, Chakraborty P, et al. Ataxia telangiectasia diagnosed on newborn screening–case cohort of 5 years’ experience. Front Immunol. (2019) 10:2940. doi: 10.3389/fimmu.2019.02940
13. Tangye SG, Al-Herz W, Bousfiha A, Chatila T, Cunningham-Rundles C, Etzioni A, et al. Human inborn errors of immunity: 2019 update on the classification from the International union of immunological societies expert committee. J Clin Immunol. (2020) 40:24–64. doi: 10.1007/s10875-019-00737-x
14. Puck JM. Newborn screening for severe combined immunodeficiency and T-cell lymphopenia. Immunol. Rev. (2019) 287:241–52. doi: 10.1111/imr.12729
15. van der Burg M, Mahlau N, Gaspar HB, Pai SY. Universal newborn screening for severe combined immunodeficiency (SCID). Front Pediatr. (2019) 7:373. doi: 10.3389/fped.2019.00373
16. Heimall J, Logan BR, Cowan MJ, Notarangelo LG, Griffith L, Puck M, et al. Immune reconstitution and survival of 100 SCID patients post hematopoietic cell transplant: A PIDTC natural history study. Blood. (2017) 130:2718–27. doi: 10.1182/blood-2017-05-781849
17. Kohn DB, Hershfield MS, Puck JM, Aiuti A, Blincov A, Gaspar B, et al. Consensus approach for the management of severe combined immunodeficiency caused by adenosine deaminase deficiency. J Allergy Clin Immunol. (2018) 143:592–603. doi: 10.1016/j.jaci.2018.08.024
18. Wilson JMG, Jungner G. World Health Organization (1968). Principles and Practice of Screening for Disease. Geneva: World Health Organization (1968). Available online at: https://apps.who.int/iris/handle/10665/37650 (accessed July 24, 2018).
19. Gaspar BH. A practical guide to implementing population newborn screening (NBS) for severe combined immunodeficiency (SCID). Int J Neonatal Screen. (2017) 3:29. doi: 10.3390/ijns3040029
20. Routes JM, Grossman WJ, Verbiski J, Laessig RH, Hoffman GL, Brokopp CD, et al. Statewide newborn screening for severe T-cell lymphopenia. JAMA. (2009) 302:2465–70. doi: 10.1001/jama.2009.1806
21. Kwan A, Abraham RS, Currier R, Brower A, Andruszewski K, Abbott JK, et al. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. JAMA. (2014) 312:729–38. doi: 10.1001/jama.2014.9132
22. Fabie NA, Pappas KR, Feldman GL. The current state of newborn screening in the United States. Pediatr Clin North Am. (2019) 66:369–86. doi: 10.1016/j.pcl.2018.12.007
23. ClinicalTrials.gov. (2014) Nantes University Hospital. Generalized Neonatal Screening of Severe Combined Immunodeficiencies (DEPISTREC). Available online at: https://ClinicalTrials.gov/show/NCT02244450.
24. de Felipe B, Olbrich P, Lucenas JM, Delgado-Pecellin C, Pavon-Delgado A, Marquez, et al. et al. Prospective neonatal screening for severe T- and B-lymphocyte deficiencies in Seville. Pediatr Allergy Immunol. (2016) 27:70–7. doi: 10.1111/pai.12501
25. Olbrich P, de Felipe B, Delgado-Pecellin C, Roderer R, Rojas P, Aguayo J, et al. A first pilot study on the neonatal screening of primary immunodeficiencies in Spain: TRECIS and KRECIS identify severe T- and B-cell lymphopenia [Spanish]. An Pediatr. (2014) 81:310–7. doi: 10.1016/j.anpede.2014.08.003
26. Blom M, Bredius RGM, Weijman G, Dekkers EHB, Kemper EA, van den Akker-van Marle ME, et al. Introducing newborn screening for severe combined immunodeficiency (SCID) in the dutch neonatal screening program. Int J Neonatal Screen. (2018) 4:40. doi: 10.3390/ijns4040040
27. Tagliaferri L, Kunz JB, Happmich M, Esposito S, Bruckner T, Okun JG, et al. Newborn screening for severe combined immunodeficiency using a novel and
simplified method to measure T-cell excision circles (TREC). Clin Immunol. (2017) 175:51–5. doi: 10.1016/j.clim.2016.11.016

28. El-Helou SM, Biegner AK, Bode S, Ehrl SR, Heeg M, Maccari ME, et al. The German National registry of primary immunodeficiencies (2012-2017). Front Immunol. (2019) 10:1272. doi: 10.3389/fimmu.2019.01272

29. National and Regional Statistical Offices: Statistical Office (https://stat.gov.pl/), Statistisches Am Mecklenburg-Vorpommern (https://www.laiv-mv.de/Statistik/) and Amt für Statistik Berlin-Brandenburg (https://www.statistik-berlin-brandenburg.de/).

30. World Health Organization. Preterm Birth. (2018) Available online at: https://www.who.int/news-room/fact-sheets/detail/preterm-birth (accessed February 19, 2018).

31. Wolf J, Dahlenburg K, Borte S. Immune cellular evaluation following newborn screening for severe primary immunodeficiency diseases in Sweden—a 2-year pilot TREC and KREC screening study. J Clin Immunol. (2017) 37:51–60. doi: 10.1007/s10875-016-0347-5

32. Borte S, von Dobelin U, Fasth A, Wang N, Janzi M, Winiarski J, et al. Neonatal screening for severe primary immunodeficiency diseases using high-throughput triplex real-time PCR. Blood. (2012) 119:2552–5. doi: 10.1182/blood-2011-08-371021

33. Graziole S, Bennett M, Hildebrandt KJ, Vallance H, Turvey SE, Junker AK. Limitation of TREC-based newborn screening for ZAP70 severe combined immunodeficiency. Clin Immunol. (2014) 153:209–10. doi: 10.1016/j.clim.2014.04.015

34. Hauck F, Blumenthal B, Fuchs S, Lenoir C, Martin E, Speckmann C, et al. SYK expression endows human ZAP70-deficient CD8 T cells with residual TCR signaling. Clin Immunol. (2015) 161:103–9. doi: 10.1016/j.clim.2015.07.082

35. Kuo CY, Chase J, Garcia, Lloreto M, Stiehm ER, Moore T, et al. Newborn screening for severe combined immunodeficiency does not identify bare lymphocyte syndrome. J Allergy Clin Immunol. (2013) 131:1693–5. doi: 10.1016/j.jaci.2013.01.019

36. Lev A, Simon AJ, Broides A, Levi J, Garty BZ, Rosenthal E, et al. Thymic function in MHC class II-deficient patients. J Allergy Clin Immunol. (2013) 131:831–9. doi: 10.1016/j.jaci.2012.10.049

37. Speckmann C, Neumann C, Borte S, la Marca G, Borte S, et al. Delayed-onset adenosine deaminase deficiency: strategies for an early diagnosis. J Allergy Clin Immunol. (2012) 130:991–4. doi: 10.1016/j.jaci.2012.04.004

38. Kwan A, Puck JM. History and current status of newborn screening for severe combined immunodeficiency. Semin Perinatol. (2015) 39:194–205. doi: 10.1053/j.semperi.2015.03.004

39. King JR, Hammarstrom L. Newborn screening for primary immunodeficiency diseases: history, current and future practice. J. Clin. Immunol. (2018) 38:56–66. doi: 10.1007/s10875-017-0455-x

40. Nourizadeh M, Shakerian L, Borte S, Fazlollahi M, Badalzadeh M, Houshmand M. Newborn screening using TREC/KREC assay for severe T and B cell lymphopnia in Iran. Scand J Immunol. (2018) 26:e12699. doi: 10.1111/sj.12699

41. Argudo-Ramírez A, Martín-Nald A, Marín-Soria JL, López-Galera RM, Pajares-García S, de Aldo-Castillo JM, et al. First universal newborn screening program for severe combined immunodeficiency in Europe. two-years’ experience in Catalonia (Spain) Front. Immunol. (2019) 10:2406. doi: 10.3389/fimmu.2019.02406

42. van der Spek J, Groenwold RH, van der Burg M, van Montfrans JM. TREC based newborn screening for severe combined immunodeficiency disease: a systematic review. J Clin Immunol. (2015) 35:416–30. doi: 10.1007/s10875-015-0152-6

43. Kraus M, Lev A, Simon AJ, Levrán I, Nissenkorn A, Levi B, et al. Disturbed B and T cell homeostasis and neogenesis in patients with ataxia telangiectasia. J Clin Immunol. (2014) 34:561–72. doi: 10.1007/s10875-014-0044-1

44. Borte S, Meeths M, Liebscher I, Krist K, Nordenskjöld M, Hammarström L, et al. Combined newborn screening for familial hemophagocytic lymphohistiocytosis and severe T- and B-cell immunodeficiencies. J Allergy Clin Immunol. (2014) 134:226–8. doi: 10.1016/j.jaci.2014.04.026

45. Lingman Framme J, Borte S, von Dobelin U, Hammarström L, Oskarsson S. Retrospective analysis of TREC based newborn screening results and clinical phenotypes in infants with the 22q11 deletion syndrome. J Clin Immunol. (2014) 34:514–9. doi: 10.1007/s10875-014-0002-y

46. Fronková E, Klöcker A, Svaton M, Novákova M, Kotová M, Kayserová J, et al. The TREC/KREC assay for the diagnosis and monitoring of patients with DiGeorge syndrome. PLoS ONE. (2014) 9:e111451. doi: 10.1371/journal.pone.0114514

47. Dimitriu A, Fauzi AS. Activation of human B lymphocytes. XI. Differential effects of azathioprine on B lymphocytes and lymphocyte subpopulations regulating B-cell function. J Immunol. (1978) 121:2335–2339

48. Kanegae MP, Barreiros LA, Sousa JL, Brito MAS, de Oliveira Junior EB, Soares LP, et al. Newborn screening for severe combined immunodeficiencies using TRECs and KRECs: Second pilot study in Brazil. Rev Paul Pediatri. (2017) 35:25–32. doi: 10.1590/1984-0462/2017;35;1;00013

49. Holodniy M, Kim S, Katzenstein D, Konrad M, Groves E, Miergan TC. Inhibition of human immunodeficiency virus gene amplification by heparin. J Clin Microbiol. (1991) 29:676–9. doi: 10.1128/JCM.29.4.676-679.1991

50. Verbsky J, Thakar M, Routes J. The Wisconsin approach to newborn screening for severe combined immunodeficiency. J Allergy Clin Immunol. (2012) 129:622–7. doi: 10.1016/j.jaci.2011.12.004

51. Kwan A, Church JA, Cowan MJ, Agarwal R, Kapoor N, Kohn DR, et al. Newborn screening for SCID and T-cell lymphopenia in California: results of the first two years. J Allergy Clin Immunol. (2013) 132:140–50. doi: 10.1016/j.jaci.2013.04.024

52. Piebani A, Soresina A, Rondelli R, Amato GM, Azzari C, Cardinale F, et al. Clinical, immunological, and molecular analysis in a large cohort of patients with X-linked agamaglobulinemia: an Italian multicenter study. Clin Immunol. (2002) 104:221–30. doi: 10.1006/clim.2002.5241

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Gizewska, Darda, Winter, Ostrowska, Oltarzewski, Klein, Blankenstein, Romanowska, Krzywiska-Zdeł, Putalan, Bartkowiak, Szczerba, Seiberling, Birkenfeld, Nauck, von Bernath, Mesiel, Bernatowska, Walczek and Pac. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.